Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on LinkedIn:
“The HIF-2α story in kidney cancer is no longer a one-drug conversation.
Arc-20 tested Casdatifan, designed for deeper, more consistent target coverage.
- Phase 1 dose-expansion, refractory metastatic clear cell RCC (100 mg QD n=32; total n=127)
- Confirmed ORR 35% at 100 mg QD, 31% across the full cohort
- Median PFS 12.2 months total, not yet reached at 100 mg QD
- Greater serum EPO suppression tracked with higher ORR (P=0.001) and longer PFS (P=0.006); tumor HIF-2α expression predicted benefit
- Class-effect anemia and hypoxia; only 3% discontinued for drug-related toxicity
Why this matters for your practice: A monotherapy signal in heavily pretreated patients that clears the belzutifan benchmark, and it comes with an on-target pharmacodynamic biomarker. Phase 3 ongoing in 2nd line in combination with cabo vs cabo monotherapy.
Would be exciting to have an early biomarker of HIF-2α response!
Congrats to Toni Choueiri, et al. Casdatifan shows durable response linked to HIF-2α biology in kidney cancer. Nature. 2026.”
Title: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Authors: Toni K. Choueiri, Jamie Merchan, Amita Patnaik, Alexandra Drakaki, Brian I. Rini, Sun Young Rha, Jae Lyun Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra Shao, Se Hoon Park, Pedro C. Barata, Bradley A. McGregor, Paul Foster, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah, Rana R. McKay.
Other articles about GU Oncology on OncoDaily.
